Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India

Summary

The purpose of the India iPro2 study is to demonstrate that iPro2 Continuous Glucose Monitoring System (CGMS) evaluation enables Health Care Professional (HCP)s treating patients in India with type 2 diabetes to get a better understanding of their patient's metabolic fluctuations, and support appropriate therapeutic intervention.

Conditions

• Diabetes Mellitus, Type 2

Interventions

BEHAVIORAL

therapy regimen

Subjects will be recommend changes in therapy regimens.

Sponsors & Collaborators

• Medtronic

  collaborator INDUSTRY

• Medtronic Diabetes

  lead INDUSTRY

Principal Investigators

• Jothydev Kesavadev, MD · Jothydev's Diabetes and Research Centre

• Mohan V, MD · Madras Diabetes Research Foundation

• Vijay Viswanathan, MD · M.V Hospital for Diabetes Research centre

• Ambrish Mithal, MD · Medanta Institute of Clinical Research

• Manoj Chawla, MD · Lina Diabetes Care Mumbai Diabetes Research Centre

• Rajiv Kovil, MD · Dr.Kovil's Diabetes Care centre

• Banshi Saboo, MD · DIA Care

• Sunil Jain, MD · TOTALL Diabetes Hormone Institute

• Abhay Mutha, MD · Diabetes Care & Research Center

• Shehla Shaikh, MD · K.G.N DIABETES AND ENDOCRINE CENTRE

• Dharmen Punatar, MD · Diab Care Centre

• Scott Lee, MD · Medtronic Diabetes

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-12-31

Primary Completion

2014-01-31

Completion

2014-04-30

Countries

• India

Study Locations